Recent news on

Doxil® Approved for Multiple Myeloma in Conjunction with Velcade®  -  25 May 2007
Cancer Consultants (press release),The US Food and Drug Administration (FDA) announced on May 17, 2007 the approval of Doxil (liposomal doxorubicin) plus Velcade for the treatment of patients

Ortho Biotech: extended Doxil approval unlikely to significantly ...  -  May 22, 2007
Pharmaceutical Business Review...'Content The FDA have approved the use of Ortho Biotech's Doxil (liposomal doxorubicin) in combination with Millennium Pharmaceuticals/Ortho Biotech's

Velcade Plus Doxil Approved For Myeloma Treatment  -  May 22, 2007
eMaxHealth.com,The combination of Doxil with Velcade provides nearly a three month improvement in time to disease progression as compared to Velcade alone, which is a 43%

US FDA approves Velcade® + Doxil® combination  -  May 22, 2007
Prdomain Business Register (press release),21 May 2007 , Bridgewater, NJ : Ortho Biotech Products, LP, today announced the US Food and Drug Administration (FDA) has approved the use of DOXIL®

The International Myeloma Foundation Reports New Drug Combination ...  -  May 22, 2007
Medical News Today (press release),The combination of Doxil(R) with Velcade(R) provides nearly a three month improvement in time to disease progression as compared to Velcade alone,

US FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of ...  -  May 21, 2007
PR Newswire (press release),The approval is based on the results of an international Phase III trial comparing the VELCADE + DOXIL combination to VELCADE alone.

Doxil/Velcade Combination Therapy Approved for Myeloma  -  May 22, 2007
Facts and Comparisons,The FDA has approved a new combination treatment, Doxil (doxorubicin liposomal) with Velcade (bortezomib), for myeloma in patients who have relapsed or have

UPDATE 2-US FDA clears J&J, Millennium cancer drug combo  -  May 18, 2007
ReutersThe Food and Drug Administration said it cleared use of J&J's drug Doxil with Millennium's Velcade in patients with multiple myeloma who have not received

New Drug Combination Improves Survival Rates for Ovarian Cancer ...  -  Mar 17, 2007
TopCancerNews.com,An article recently published in the Annals of Oncology says that treatment consisting of Doxil and carboplatin may improve survival in patients with

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 15, 2007
Cancer Consultants (press release),Only 2 patients received Velcade alone with the remainder receiving Velcade combined with dexamethasone, dexamethasone and Thalomid, Doxil and Thalomid or

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 14, 2007
Cancer Consultants (press release),Two patients were treated with Velcade alone, while the others were treated with Velcade combined with dexamethasone, dexamethasone and Thalomid®, Doxil®

An Israeli Biotech Company Plays the Field  -  Mar 13, 2007
BusinessWeekThey include multiple sclerosis drugs Copaxone and Rebif, from Teva and Merck Serono (SRA), respectively; and Doxil, an ovarian cancer drug from Johnson

Morgan Stanley overweight on Sun Pharmaceutical  -  Mar 13, 2007
Moneycontrol.com,Mid-term valuation drivers: Commercialization of Able/Valiant pipelines and research/regulatory progress of generic Lupron and Doxil.

Doxil®/Paraplatin® Effective in Recurrent Ovarian Cancer  -  Feb 21, 2007
Cancer Consultants (press release),According to an article recently published in the Annals of Oncology, treatment consisting of Doxil® (pegylated liposomal doxorubicin) and Paraplatin®

Supplemental New Drug Application Accepted for Doxil® Plus Velcade ...  -  Feb 6, 2007
Cancer Consultants (press release),The United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination of Doxil (pegylated

Patients with Hodgkin’s Lymphoma at Risk for Heart Attack Later in ...  -  Feb 16, 2007
Cancer Consultants (press release),There are now alternatives to doxorubicin such as Doxil which may be less toxic. Reference: Swerdlow A, Higgins C, Smith P, et al.

ALICIA'S STORY Goodbye, interferon, hello, chemo -- new step in ...  -  Feb 2, 2007
San Francisco Chronicle,I took the next day off from work, did some research on Google Scholar (not much new, except that Doxil had been used on a few ASPS patients,

Millennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP ...  -  Feb 8, 2007
PR Newswire (press release),Ortho Biotech Products, LP announced on January 22, 2007 that the FDA accepted an application for priority review of DOXIL as combination therapy with

Newly-Published Study Shows CAELYX(R) Plus Carboplatin to Be ...  -  Feb 16, 2007
netPR.pl (komunikaty prasowe),The product is marketed in the United States under the trade name DOXIL(R) by Ortho Biotech Products, LP. Schering-Plough Corporation is a global

Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination ...  -  Dec 11, 2006
PR Newswire (press release),The study results demonstrate that patients who received a combination of DOXIL and VELCADE had 45 percent less risk of their disease progressing and a

Doxil® and Paraplatin® Effective for Recurrent Ovarian Cancer  -  Nov 30, 2006
Cancer Consultants (press release),Doxil is an active single agent for the treatment of refractory or resistant ovarian cancer and has been approved by the US Food and Drug Administration for

Drug Combination Slows Progression Of Treatment Resistant Bone ...  -  Dec 16, 2006
Medical News Today (press release),The study was supported by Johnson & Johnson, which owns Ortho Biotech, the maker of Doxil, and also has a financial interest in Velcade.

VELCADE(R) For Injection Based Therapies Show Consistently High ...  -  Dec 13, 2006
Medical News Today (press release),High Rate of Complete and near Complete Responses after Initial Therapy with VELCADE (Bortezomib), DOXIL, and Dexamethasone (VDD) Is Further Increased after

VELCADE(R) (Bortezomib) for Injection Based Therapies Show ...  -  Dec 12, 2006
PR Newswire (press release),DOXIL at 30 mg/m2 was administered on day four and dexamethasone at 40 mg on days one to four for the first 10 patients and at 20 mg on days 1, 2, 4, 5, 8,

VELCADE(R) (Bortezomib) for Injection Based Therapies Show ...  -  Dec 12, 2006
Drug Newswire (press release),The Phase II clinical trial evaluated VELCADE in combination with DOXIL plus dexamethasone (VDD) in 28 evaluable newly diagnosed MM patients.

Positive Results from Combination Trials Build on Bortezomib for ...  -  Dec 14, 2006
DG NewsThe randomized, multicenter Phase III trial is evaluating the efficacy and safety of Velcade in combination with Doxil in 646 relapsed MM patients who had

Millennium, J&J combination delays cancer progression  -  Dec 13, 2006
Pharmaceutical Business ReviewResearchers have suggested that the combination of Johnson & Johnson's Doxil and Millennium Pharmaceuticals' Velcade provides a nearly three-month

Millennium, J&J drug combo adds impact in myeloma  -  Dec 11, 2006
ReutersBased on an interim analysis of the late-stage, or Phase III, trial of Velcade in combination with Doxil, an independent data monitoring board determined

Millennium Pharmaceuticals (MLNM) Reports Results from Clinical ...  -  Dec 11, 2006
StreetInsider.com (subscription),As a result, patients receiving VELCADE in the study were offered the opportunity to add DOXIL to their regimen. The trial is ongoing.

Clinical Data on Thalidomide in Multiple Myeloma and Other ...  -  Dec 7, 2006
Drug Newswire (press release),VAD-doxil + Thalidomide as Initial Treatment in Patients. Oral Presentation at 8:45 am on Monday, Dec. 11; 7:30-9:00 am;

Market Report -- In Play (MLNM)  -  Dec 12, 2006
MSN Money...variety of agents, including DOXIL (pegylated liposomol doxorubicin) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients.

Market Report -- In Play (MLNM)  -  Dec 11, 2006
MSN MoneyVELCADE in combination with DOXIL achieved a statistically significant improvement in time to disease progression (TTP), the primary endpoint of the

Positive Results from Combination Trials Build on VELCADE(R ...  -  Dec 11, 2006
PR Newswire (press release),Three hundred twenty-four patients received the same dose and schedule of VELCADE with the addition of DOXIL at 30 mg/m2 given on day four of each cycle.

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
PR Newswire (press release),VAD-doxil Plus Thalidomide in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group; Abstract 0794 * A Randomized,

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
Drug Newswire (press release),VAD-doxil Plus Thalidomide in Patients with Multiple. Diagnosed MM. Combined Results of IFM 99 Trials; Abstract 3077. Event? Summary of 4 Cases at a Single

Clinical Data on Thalidomide in Multiple Myeloma and Other ...  -  Dec 7, 2006
PR Newswire (press release),VAD-doxil + Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group Abstract ID:

Understand How Nanotechnology is Revolutionizing Drug Delivery  -  Dec 19, 2006
PharmaLive.com (press release),Abraxane and Doxil are both innovative marketed oncology products utilizing nanotechnology, gaining sales of $184m and $177m in the US and 5 major European

Sector Wrap: Hematology Meeting  -  Dec 11, 2006
Forbes,Millennium Pharmaceuticals Inc. and Johnson & Johnson Inc. said researchers found a combination of Millennium's Velcade, and Doxil, made by J&J's Ortho

(PRN) - Revolutionary, All-in-One Spa Bed Combines Tanning With ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time to Progression in Previously Treated Multiple Myeloma Patients .

Significant Data on VELCADE(R) (bortezomib) For Injection To Be ...  -  Dec 8, 2006
PR Newswire (press release),Ph.D., University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan * Preliminary data from a study of VELCADE plus Doxil and dexamethasone

Drug studies at KMC target rare cancer  -  Dec 8, 2006
Spokane Journal of Business,...to start enrolling patients in an experiment involving Yondelis and a drug called doxil that’s used to treat advanced ovarian cancer.

Amrubicin Shows Promise in Relapsed or Refractory Small Cell Lung ...  -  Dec 7, 2006
Cancer Consultants (press release),However, when there is concern about cardiac toxicity, there are currently FDA-approved drugs such as Doxil®, that are less cardio-toxic than Adriamycin.

Novel approach to detoxifying cancer drugs  Nov 7, 2006
..."The dendrimer is as good as Doxil. ... Szoka is the scientific founder of Sequus Pharmaceuticals Inc., the Menlo Park company that invented the Doxil product. ... -UC Berkeley, Doxil®, Oncovin®, Dexamethasone and Revlimid®: Safe and ...  Nov 3, 2006
29% of patients with relapsed or refractory multiple myeloma achieve complete or near complete remissions following treatment with Doxil (pegylated doxorubicin ... -Cancer Consultants (press release), Doxil®, Oncovin®, Revlimid®, and Dexamethasone Effective in ...  Oct 30, 2006
...published in Annals of Oncology, the treatment combination consisting of Revlimid® (lenalidomide), Oncovin® (vincristine), Doxil® (pegylated doxorubicin ... -Cancer Consultants (press release), Delivering on Nano's Promise  Oct 9, 2006
In 1995, several years before the word nanotechnology began creating a buzz, Doxil (doxorubicin HCL liposome injection) received accelerated approval for the ... -Drug Discovery & Development, Millennium Pharmaceuticals Q3 2006 Earnings Call Transcript  Oct 26, 2006
No, but you can think about that they are promoting very large products of Procrit and they also have Doxil and they will also have VELCADE. -Seeking Alpha, Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice ...  Oct 9, 2006
...in clinical development, including registration strategies and expansion of label, for multiple oncology therapeutics including Neupogen, Doxil (for the ... -Drug Newswire (press release), Thalomid®, Doxil® and Dexamethasone Effective in Elderly with ...  Sep 22, 2006
Researchers from Italy have reported that a regimen of Thalomid (thalidomide), Doxil® (Caelyx® in Europe) (pegylated doxorubicin) and dexamethasone is very ... -Cancer Consultants

Doxil®/Gemzar® Confirmed Effective for Recurrent Ovarian Cancer  Sep 1, 2006
Researchers from Austria have confirmed that the combination of Doxil (pegylated liposomal doxorubicin) and Gemzar (gemcitabine) is active and well tolerated ... -Cancer Consultants

Doxil®/Gemzar® Effective for Recurrent Ovarian Cancer  Aug 31, 2006
...to an article recently published in Gynecologic Oncology, the chemotherapy combination consisting of Gemzar® (gemcitabine) and Doxil® (pegylated liposomal ... -Cancer Consultants

Addition of Gemzar® to Paraplatin® Improves Progression-Free ...  Sep 20, 2006
There are a variety of chemotherapy agents available for the palliative treatment of recurrent ovarian cancer including: Doxil® (pegylated doxorubicin ... -Cancer Consultants

ThermoDox(TM) Animal Studies to Be Presented at 6th International ...  Aug 31, 2006
...today announced that a study treating tumors in mice with either ThermoDox combined with pulsed high intensity focused ultrasound (HIFU) or Doxil(R) combined ... -International News Service

Ovarian cancer: platinum-based therapy still the gold standard  Sep 11, 2006
...also other drugs such as Eli Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan) and Ortho Biotech/Schering Plough's Doxil/Caelyx (liposomal ... -Pharmaceutical Business Review

Examine Emerging Opportunities in Cancer Nanomedicine With This ...  Sep 4, 2006
Gilead Sciences/Diatos - CellSearch Circulating Tumor Cell Kit - Immunicon - Bio-barcode and Verigen platform - Nanosphere - Caelyx/Doxil - Ortho Biotech ... -International News Service

Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination ...  -  12 Dec 2006
Medical News Today (press release),The study results demonstrate that patients who received a combination of DOXIL and VELCADE had 45 percent less risk of their disease progressing and a

Clinical Data on Thalidomide in Multiple Myeloma and Other ...  -  Dec 7, 2006
Drug Newswire (press release),VAD-doxil + Thalidomide as Initial Treatment in Patients. Oral Presentation at 8:45 am on Monday, Dec. 11; 7:30-9:00 am;

Full Text  -  Nov 23, 2006
Science Magazine (subscription)Doxil is a liposomal formulation that encapsulates doxorubicin, a widely used DNA-damaging chemotherapeutic agent. Liposome-encapsulated doxorubicin has

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
PR Newswire (press release),VAD-doxil Plus Thalidomide in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group; Abstract 0794 * A Randomized,

(PRN) - Revolutionary, All-in-One Spa Bed Combines Tanning With ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time to Progression in Previously Treated Multiple Myeloma Patients .

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
Drug Newswire (press release),VAD-doxil Plus Thalidomide in Patients with Multiple. Diagnosed MM. Combined Results of IFM 99 Trials; Abstract 3077. Event? Summary of 4 Cases at a Single

Clinical Data on Thalidomide in Multiple Myeloma and Other ...  -  Dec 7, 2006
PR Newswire (press release),VAD-doxil + Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group Abstract ID:

Doxorubicin-Loaded Dendrimer Offers Hope for Colon CA  -  Nov 14, 2006
Medgadget.com,The mice were injected with colon cancer cells, and several days later with doxorubicin, doxorubicin-dendrimer or Doxil. Though the latter two cured the

Significant Data on VELCADE(R) (bortezomib) For Injection To Be ...  -  Dec 8, 2006
PR Newswire (press release),Ph.D., University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan * Preliminary data from a study of VELCADE plus Doxil and dexamethasone

Drug studies at KMC target rare cancer  -  Dec 8, 2006
Spokane Journal of Business,...to start enrolling patients in an experiment involving Yondelis and a drug called doxil that’s used to treat advanced ovarian cancer.

Amrubicin Shows Promise in Relapsed or Refractory Small Cell Lung ...  -  Dec 7, 2006
Cancer Consultants (press release),However, when there is concern about cardiac toxicity, there are currently FDA-approved drugs such as Doxil®, that are less cardio-toxic than Adriamycin.

Child Cancer Survivors Need Long Term Heart Follow-up  Aug 22, 2006
It involved 22 long-term survivors of bone cancer who were treated with doxorubicin (sold as Adriamycin, Doxil, and Rubex) between 1977 and 1990. ... -ACS News Center

A CANCER WARRIOR  Jul 31, 2006
...her insurance. Finally, a clear bag containing 70 milligrams of Doxil is brought into her room and hung from an IV pump. The nurse ... -Columbus Dispatch

Char Andrews spent months preparing for her death, but she spent ...  Aug 14, 2006
She told them about passing a heart test so that she could start Doxil, another in a long line of chemotherapy drugs she had been taking continuously for 4 1/2 ... -Statesman Journal

Doxil Receives Full FDA Approval  Jun 30, 2006
The FDA has granted full approval to Doxil® (doxorubicin HCI liposome injection) for the treatment of ovarian cancer that has advanced or recurred after ... -Cancer Consultants

High-dose Dense Chemotherapy and Radiation Therapy for Women with ...  Jul 21, 2006
Attempts to decrease cardiotoxicity include the use of liposomal compounds such as Doxil® (liposomal doxorubicin) and the administration of protective agents ... -Cancer Consultants

ODAC Committee to Meet Nov. 8 On Accelerated Approval Commitments  Jun 30, 2006
In its deliberations, the committee will review the status of Phase IV commitments for Johnson & Johnson/Alza’s Doxil® (liposomal doxorubicin), MedImmune ... -Cancer Consultants

BioLineRx In-Licenses Novel Orally-Available Peptide for the ...  Jul 17, 2006
Notable successes in the medical field include Exelon(TM), the Alzheimer's and dementia medication sold by Novartis and Doxil(TM), the cancer treatment sold by ... -Genetic Engineering News

Bortezomib in Combination With Liposomal Doxorubicin and ...  Jun 21, 2006
AMSTERDAM, THE NETHERLANDS -- June 21, 2006 -- The combination of bortezomib (Velcade(R)) with pegylated liposomal doxorubicin (Doxil(R)) and thalidomide (VDT ... -DG News

Joseph Vallner Joins Lumera's Board; Adds Industry Leadership and ...  Jun 28, 2006
Prior to Cell Genesys, he was with SEQUUSPharmaceuticals for seven years where he was instrumental in thelaunch of two products including Doxil(R), a liposome ... -Finanzen.net

Updates for Application Approvals and Orphan Drug Status Approvals  Jun 30, 2006
Velcade® is now fully approved in relapsed multiple myeloma. The USP has approved Doxil® for a new indication: multiple myeloma. ... -Cancer Consultants



Herceptin® Plus Doxil® Safe and Effective in Metastatic Breast ...  16 May 2006
...online publication in the Journal of Clinical Oncology, the treatment combination consisting of Herceptin® (trastuzumab) plus Doxil® (pegylated liposomal ... - Cancer Consultants

CA-125 May Not Be Reliable Marker for Response to Doxil® In ...  May 3, 2006
...at the 2005 annual meeting on Women’s Cancer™, early CA-125 levels were not consistently reliable as a measure of response to Doxil® (doxorubicin HCl ... - Cancer Consultants

Telik Announces Initiation of New TELCYTA Phase 3 Clinical Trial ...  May 2, 2006
...the initiation of ASSIST-5, an international Phase 3 clinical trial that will compare treatment with the combination of TELCYTA® and Doxil® to treatment with ... - Yahoo! News

Telik Announces Initiation Of New TELCYTA Phase 3 Clinical Trial ...  May 3, 2006
...announced the initiation of ASSIST-5, an international Phase 3 clinical trial that will compare treatment with the combination of TELCYTA(R) and Doxil(R) to ... - Medical News Today

Telik Begins Phase III Trial in Resistant Ovarian Cancer  May 7, 2006
In the trial, dubbed ASSIST-5, approximately 244 women will be randomized to receive either a combination of Telcyta plus Doxil, a chemotherapeutic which is ... - International News Service

Telik Announces Financial Results for 2006 First Quarter  May 4, 2006
Initiation of the ASSIST-5 trial: This Phase 3 trial will evaluate the combination of TELCYTA plus Doxil(R) to treatment with Doxil alone in women with ... - PharmaLive.com

Telik Launches Phase III Ovarian Cancer Treatment Trial  May 2, 2006
Phase III clinical trial that will compare treatment with a combination of its lead drug candidate, Telcyta, and Johnson & Johnson's (JNJ) Doxil to treatment ... - Therapeutics Daily (subscription)

Telik Announces Financial Results for 2006 First Quarter  May 4, 2006
Recent highlights include: -- Initiation of the ASSIST-5 trial: This Phase 3 trial will evaluate the combination of TELCYTA plus Doxil(R) to treatment with ... - PR Newswire

Cardioxane® (Dexrazoxane) Reduces Anthracycline-Induced Cardiac ...  May 10, 2006
Attempts to decrease cardiotoxicity include the use of liposomal compounds such as Doxil® (liposomal doxorubicin) and the administration of protective agents ... - Cancer Consultants

The hardest part of hope  Apr 17, 2006
...got. Then there are side effects. When I was on Doxil, my mouth and throat were full of blisters. I couldn't eat anything solid. ... - Macon Telegraph

ThinkEquity Partners LLC Hosts a Panel Discussion on Ovarian ...  Apr 19, 2006
The forum includes a distinguished team of doctors who will address current ovarian cancer treatments such as Doxil, Hycamptin and the platinums and ... - Market Wire





J&J: Taking Stock of a Household Name  11 Apr 2006
During 2006-07, we anticipate the potential launch of products including OROS Hydromorphone for chronic pain, DOXIL for multiple myeloma and breast cancer ... - BusinessWeek

Matrix Metalloproteinase Inhibitor Effective for Kaposi’s ...  Mar 22, 2006
Patients with AIDS-related Kaposi’s sarcoma are initially treated with Doxil (liposomal doxorubicin) or combination chemotherapy with doxorubicin, bleomycin ... - Cancer Consultants

LIPOSOME RESEARCHERS SEEK TO STOP BIRD FLU BEFORE IT TAKES FLIGHT  Mar 27, 2006
Researchers trying to modulate the side effects of the powerful breast cancer chemotherapy Adriamycin made a new variety of it called Doxil that is carried by ... - Small Times

Patients with NHL Treated with Anthracyclines at Long-Term Risk ...  Mar 27, 2006
...question, which can only be asked with long-term studies, is whether or not the newer pegylated and lysosomal anthracyclines, such as Doxil®, will have an ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional